ICI-PMR irAEs are sometimes underestimated compared to inflamm arthritis, but why? ICI-IA and ICI-PMR look different, but at @HSpecialSurgery, steroid needs and disease impact for both are basically the same. Let’s not devalue either @lovetolearn27 #EULAR2025 POS1200 @RheumNow https://t.co/NVq2tpjvdu

#EULAR2025 Abstr#POS0301 Real World Multicentre study in Italy reported higher proportion of CRR at 6-mth & Lower GC in people with #lupus nephritis (~96% Class III, IV or Mixed with V) treated with Belimumab+SOC vs matched cohort on SOC. Predicted by early BEL use @RheumNow https://t.co/D6e2qo9NRL

✅Exciting results from POETYK PsA-1: -Deucravacitinib (TYK2i) in PsA -ACR 20 was achieved in significantly more patients treated with deucravacitinib vs placebo at W16 (54.2% vs 34.1%; P < 0.0001), with similar results for ACR 50 and ACR 70 -Also met 2dary endpoints. -Post hoc https://t.co/S4DhovMCma

Hidradenitis suppurativa is newer to us in rheumatology, but it seems like inflamm arthritis is a problem - at least to a similar extent as in psoriasis. Time for us to look for it & to see what therapies like IL-17 inhibitors do for this arthritis #EULAR2025 POS1237 @RheumNow https://t.co/b5EQdDEAhq

Social disparities in rheumatology @RheumNow #EULAR2025 ~70% of outcomes are determined by Social determinants of health Modifiable factors ? Maybe? https://t.co/UfC2nQ5Azy

@RheumNow Achieving health equity is the goal 1.4% of GDP is lost in health inequity in EU https://t.co/50M4SfuxvX

How much of the health outcomes are related to social determinants? 🔺️Up to 75%! Disaster Medicine Session Social disparities and impact on outcomes Dr Kate Webb #EULAR2025 @RheumNow https://t.co/0Ahbf79Nbx

#EULAR2025 Abstr#LB0007 Two’s Company, Three’s a Crowd! In 5 #SLE pts treated with CC312, a novel CD19/CD3/CD28 tri-specific ab in dose escalation showed rapid & B-cell depletion & all achieved SRI-4. No =>G2 CRS or ICANS. USP: off-the-shelf & overcome T-cell exhaustion @RheumNow https://t.co/6DZRj09JEQ

Low disease activity more difficult to achieve in vulnerable populations. All rheumatic diseases - #RA #PsA #AS initiating DMARDs takes longer in these population #EULAR2025 @RheumNow https://t.co/voIivshKRt

What do we know about disparities in #SLE - worse in women - worse in non white populations - have lower quality of care in vulnerable populations - have worse outcomes in vulnerable populations #EULAR2025 @rheumnow Diagnosis itself is difficult in communities with poor access https://t.co/pcUaJ0eK65

#Lupus is one of the biggest social discriminators 🔺️Higher prevalence in Women 🔺️Higher prevalence in Non-Whites 🔺️More catastrophic manifestations in low socioeconomic groups Disaster Medicine Session Social disparities and impact on outcomes #EULAR2025 @RheumNow https://t.co/mewR9NzXHt

Dual pandemic in Africa. Increasing lifestyle diseases and obesity, along with infections and malnutrition. These may be reflected in rheumatic diseases too (if they could be studied in detail) #EULAR2025 @RheumNow https://t.co/6ulMRxX8az